Viking Therapeutics (VKTX) to Release Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is projected to announce its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Viking Therapeutics Price Performance

Shares of NASDAQ VKTX opened at $34.32 on Wednesday. The stock has a market cap of $3.82 billion, a PE ratio of -36.90 and a beta of 0.95. The firm has a fifty day moving average price of $43.29 and a 200-day moving average price of $55.04. Viking Therapeutics has a 1 year low of $21.26 and a 1 year high of $99.41.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on VKTX shares. StockNews.com raised Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. HC Wainwright restated a “buy” rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Friday, January 17th. Piper Sandler assumed coverage on Viking Therapeutics in a research note on Monday, December 2nd. They set an “overweight” rating and a $74.00 price target for the company. Finally, B. Riley initiated coverage on Viking Therapeutics in a report on Friday, November 22nd. They set a “buy” rating and a $109.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $106.75.

Insider Buying and Selling at Viking Therapeutics

In related news, COO Marianna Mancini sold 54,215 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the transaction, the chief operating officer now owns 374,134 shares in the company, valued at $15,994,228.50. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total value of $137,340.00. Following the completion of the sale, the director now owns 47,965 shares in the company, valued at approximately $3,293,756.55. The trade was a 4.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 301,014 shares of company stock worth $12,920,189 over the last quarter. Insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.